If one of your clinical research sites has received an FDA warning letter or FDA Form 483, your first instinct may be to panic. It may also be tempting to look for someone to blame, which is equally unhelpful.
Topics: Form 483, FDA, Warning Letters
You want to keep your trial on track, but physical distancing and travel restrictions have made it difficult. Fortunately, IMARC has experience providing remote services.
If one of your clinical research sites has received an FDA warning letter or FDA Form 483, your first instinct may be to panic. It may also be tempting to look for someone to blame, which is equally unhelpful.
Topics: Form 483, FDA, Warning Letters
Medical device manufacturers know that the FDA can inspect their establishment any time,
Topics: Form 483, Medical Device Manufacturers, FDA
Following an FDA inspection, a clinical research site may be issued an FDA Form 483 or a warning letter.
The Form 483 and FDA Warning Letter both serve a similar purpose—to inform sponsors and principal investigators of issues requiring corrective action—but there are some important differences. A Form 483 is less formal but can escalate to a warning letter in the same way a tornado watch becomes a more serious warning.
Read on to learn the differences between Form 483s and FDA Warning Letters, as well as potential changes on the horizon.
Topics: Form 483, FDA, Warning Letters
Your friends from the FDA stopped by and noted several red flags at your site in a Form 483. Now what? The most important thing you can do as a principal investigator is accept responsibility for these violations and demonstrate you're taking steps to address them.
Topics: Form 483, Principal Investigator, FDA
Each year, IMARC releases a whitepaper listing of the top reasons for FDA warning letters, here is the listing for 2015. Provided below are 10 Tips to consider when responding to a FDA Warning Letter or Form 483:
Topics: Form 483, FDA Warning Letters
You’ve received “the call” from the FDA auditor. After an understandable quick moment of panic, what should your next steps be?
Topics: Form 483, Audit Prep, BIMO Checklist, FDA
This week is FDA Warning Letter Week at IMARC! Have you had a chance to catch up on the first three blogs that aim to help you response to the FDA? This last blog in the series attempts to take the perspective of the agency when reading your response letters.
Topics: Form 483, FDA, Warning Letters
This week is FDA Warning Letter Week at IMARC! Did you check out the first blog in a series of 4 titled Differences and similarities between FDA Warning Letters and Form 483s? Next learn the Top 10 “Do NOT” tips when responding to an FDA Warning Letter or Form 483:
Topics: Form 483, FDA Warning Letters, FDA Responses
It hit the headlines in a dizzy twist on words. The CEO of St. Jude put the cart before the horse in warning investors that he was expecting a warning letter from FDA before one was actually even issued! According to a report on MedCity News, this type of announcement apparently has no precedent. Have you ever heard of a company proactively telling Wall Street they’re going to receive the dreaded warning letter before receiving it- or even a FDA form 483? This was something that was on the mind of analyst Bob Hopkins of Bank of America.
Topics: Wall Street, Form 483, Medical Devices, FDA